...as the venture arm of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), SR One was spun out last year.Surface Oncology Inc. (NASDAQ:SURF...
...GenScript in September. No formal change has been made against Zhang, the company said. BC Staff SR One Surface Oncology Inc. Agenus...

...COVID-19. " title="Interactive or visual content" frameborder="0" scrolling="no" style="width:100%;height:900px;"> Selina Koch AstraZeneca plc Arcus Biosciences Bristol-Myers Squibb Co. I-Mab Biopharma Akeso Biopharma Surface Oncology Inc. Novartis...

...types against tumors. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) announced Thursday that it licensed an anti-PVRIG mAb from Surface Oncology...

...Senior Editor GlaxoSmithKline’s $85 million deal with Surface Oncology...
...pharma pipelines. On Thursday, the partners announced that Surface Oncology Inc....
...cell immunoglobulin and mucin domain 3 Lauren Martz GlaxoSmithKline plc Surface Oncology Inc....

...The company’s shares lost $6.51 (59%) to $4.53 on Monday.Surface Oncology lifts on M&A reportImmuno-oncology company Surface Oncology Inc....

...He is a strategic adviser at Third Rock Ventures and chairs bluebird bio Inc. (NASDAQ:BLUE), Surface Oncology Inc....

...see “French VC Sofinnova Expanding Start-up Ecosystem in Italy” ). Surface Oncology gains on Merck deal Surface Oncology Inc....
...focus on gastric cancers that have developed resistance to checkpoint inhibition. The stock move brings Surface Oncology’s...
...sch 066336) SRF617 Keytruda, pembrolizumab (MK-3475, lambrolizumab) Gilead Sciences Inc. Galapagos N.V. Merck & Co. Inc. Eiger BioPharmaceuticals Inc. eGenesis Inc. ICB International Sofinnova Partners Surface Oncology Inc. San...

...they all look very different.” Jeff Goater, Surface Oncology However, early clinical studies, in particular by Surface Oncology Inc....
...further dose escalation/expansion.” A separate Phase I trial in combination with Rituxan rituximab is ongoing. Surface Oncology Inc....
...China Novimmune S.A., Plan-les-Ouates, Switzerland OSE Immunotherapeutics S.A. (Euronext:OSE), Nantes, France Stanford University, Stanford, Calif. Surface Oncology Inc....

...different phases of red blood cell development. Surface, Innate show preclinical efficacy for immunometabolism mAbs Surface Oncology Inc....
...EpoR - Erythropoietin receptor Sandi Wong, Staff Writer IPH52, IPH5201 IPH53 LVGN6051 MRNA-1944 SRF373 (NZV930) SRF617 Innate Pharma S.A. Lyvgen Biopharma Co. Ltd. Moderna Inc. Stanford University Surface Oncology Inc. University...

...extracellular lipoprotein APOE4, which plays a role in neurodegenerative diseases, as well as the cell surface oncology...